Capricor Therapeutics Inc (CAPR): Capricor Therapeutics NASDAQ: CAPR Cel...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	495
Posts	32172
Boards Moderated	0
Alias Born	03/12/2014

Volcano

Re: None

Saturday, 09/17/2022 8:34:14 PM

Saturday, September 17, 2022 8:34:14 PM

Capricor Therapeutics
NASDAQ: CAPR
Cell and Exosome-Based Platform Therapeutics Company
Enrolling Phase 3 in Duchenne Muscular Dystrophy
• Strategic partnership: $705 million in potential milestones
• Market potential over $1 billion annual sales
• Positive phase 2 data published in The Lancet
Exosomes Platform Expansion
• Natural intracellular delivery technology for RNA and proteins
Broad Scientific and Intellectual Property Profile
• Over 100 publications from multiple institutions worldwide
• Over 100 granted and pending patents
Strong External Collaborations
Headquarters: San Diego, California NASDAQ: CAPR
Founded: 2006, public in 2013 Outstanding Shares: 24.3M Employees: ~65
• US Army, US Department of Defense, Johns Hopkins University, Cedars-Sinai Medical Center
and Nippon Shinyaku, Co.
Cash Runway for approximately 2 years